Shengfang Jin, Ensem Therapeutics president and CEO
November 21, 2023 07:14 AM EST
Deals

BeiGene li­cens­es CDK2 in­hibitor from En­sem in po­ten­tial $1.33B deal

Katherine Lewin

News Reporter

BeiGene has struck a deal with En­sem Ther­a­peu­tics to li­cense an oral cy­clin-de­pen­dent ki­nase 2 (CDK2) in­hibitor in ex­change for an undis­closed up­front pay­ment and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times